The FDA approves Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi’s (NYSE:SNY) PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma, the second most common type of skin cancer.
The U.S. list price will be $9,100 per three-week cycle.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.